Figure 3.
Effect of benzolamide on evoked [Ca2+]e transients in APV. A, Traces obtained in standard ACSF. Left shows overlay of a control trace (Ctl, black trace) and the diminished response after application of 50 μm APV (gray trace). Right displays the same record in APV (gray trace) and overlay of a trace after subsequent addition of benzolamide (Bz, dashed black trace). Note the increase in duration, with no change in amplitude. B, Mean effects of benzolamide in standard ACSF. Left displays the mean normalized response amplitudes. There was no significant difference for APV versus APV plus benzolamide (NS, p > 0.05). Differences for control versus APV and control versus APV plus benzolamide were significant (p < 0.01) but were not displayed for clarity. Right displays the mean normalized decay half-times. Note the significant increase in decay half-time after addition of benzolamide. C, Traces obtained in 0 Mg2+/PTX ACSF, displayed as in A. APV diminished the [Ca2+]e transient (left), and subsequent addition of benzolamide (right) prolonged the decay half-time in this instance by 42%, with no effect on its amplitude. D, Mean effects of benzolamide in 0 Mg2+/PTX ACSF. Left, Normalized response amplitude with no significant difference for APV versus APV plus benzolamide. Differences between control versus APV and control versus APV plus benzolamide were significant but were not displayed for clarity. Right, Normalized differences in the decay half-time. On average, the decay time in APV was approximately doubled after addition of benzolamide.